candesartan cilexetil has been researched along with Cerebral Ischemia in 4 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neurovascular protection against cerebral ischemia is not consistently observed with a postischemia hypotensive dose of candesartan." | 7.77 | Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. ( Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011) |
| "Neurovascular protection against cerebral ischemia is not consistently observed with a postischemia hypotensive dose of candesartan." | 3.77 | Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia. ( Fu, H; Hosomi, N; Itano, T; Kohno, M; Liu, G; Masugata, H; Matsumoto, M; Miki, T; Nakano, D; Nishiyama, A; Pelisch, N; Sueda, Y; Ueno, M, 2011) |
| "Stroke is one of the leading causes of invalidism and death in the industrialized world." | 2.42 | Are angiotensin receptor blockers neuroprotective? ( Gerova, N; Krikov, M; Li, J; Neumann, C; Thöne-Reineke, C; Unger, T; Zimmermann, M, 2004) |
| " In human umbilical endothelial cells, candesartan increased the eNOS protein level AT2-R dependently, inhibited the expression of nicotinamide adenine dinucleotide phosphate oxidase subunits and angiotensin II-induced intracellular reactive oxygen species and nitric oxide, and promoted the extracellular release of nitric oxide, suggesting that it augmented the bioavailability of nitric oxide." | 1.35 | Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies. ( Kanematsu, Y; Kinouchi, T; Kitazato, KT; Liu, H; Nagahiro, S; Tada, Y; Tamura, T; Uno, M; Yagi, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Kitazato, KT | 1 |
| Uno, M | 1 |
| Yagi, K | 1 |
| Kanematsu, Y | 1 |
| Tamura, T | 1 |
| Tada, Y | 1 |
| Kinouchi, T | 1 |
| Nagahiro, S | 1 |
| Fu, H | 1 |
| Hosomi, N | 1 |
| Pelisch, N | 1 |
| Nakano, D | 1 |
| Liu, G | 1 |
| Ueno, M | 1 |
| Miki, T | 1 |
| Masugata, H | 1 |
| Sueda, Y | 1 |
| Itano, T | 1 |
| Matsumoto, M | 1 |
| Nishiyama, A | 1 |
| Kohno, M | 1 |
| Michel, P | 1 |
| Bogousslavsky, J | 1 |
| Thöne-Reineke, C | 1 |
| Zimmermann, M | 1 |
| Neumann, C | 1 |
| Krikov, M | 1 |
| Li, J | 1 |
| Gerova, N | 1 |
| Unger, T | 1 |
1 review available for candesartan cilexetil and Cerebral Ischemia
| Article | Year |
|---|---|
Are angiotensin receptor blockers neuroprotective?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2004 |
3 other studies available for candesartan cilexetil and Cerebral Ischemia
| Article | Year |
|---|---|
Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain Ischemia | 2008 |
Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2011 |
ACCESS study: blood pressure effect?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |